Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Provincial squeeze on generic prices continues

donalee Moulton
CMAJ October 04, 2011 183 (14) E1049-E1050; DOI: https://doi.org/10.1503/cmaj.109-3966
donalee Moulton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

The clampdown on generic drug payments is becoming a nationwide vise as Nova Scotia has joined the bevy of provinces who’ll reduce prices paid for knockoffs.

Under Nova Scotia’s new “Fair Drug Pricing Act,” the province’s pharmacare program will pay just 45% of the cost of a brand drug for an equivalent generic. Over the next year, the cap will drop to 35%.

“Nova Scotia is just following a trend started by Ontario last year,” says Marc-André Gagnon, an assistant professor with the School of Public Policy and Administration at Carleton University in Ottawa, Ontario.

Ontario launched the trend toward reducing provincial drug payments by reducing payments for generics to 25% of the list price of the original brand product in the province’s drug benefit program.

The benefits of Ontario’s July 2010 decision will eventually flow through to consumers, says Andrew Morrison, spokesperson for the Ministry of Health and Long-Term Care in Toronto. There will be “a gradual decrease in generic drug pricing in the private market over the next three years for private employer drug plans and people who pay for drugs out of pocket.”

Quebec, British Columbia and Saskatchewan have since followed suit, while Alberta is currently reviewing a similar strategy.

Two key factors are fueling the measures, says Ingrid Sketris, professor of pharmacology at Dalhousie University in Halifax, Nova Scotia. “People are concerned with high drug costs and having a sustainable system.”

Others say that with many brand-name drugs coming off patent in the next few years, the provinces are looking to curb costs by reducing the amount they’ll pay for generics. “There was a profusion of drugs through the ‘80s and ‘90s. Those that were new are coming off patent. Governments are hoping for a substantial windfall,” notes Dr. David Henry, professor of medicine at the University of Toronto in Ontario and CEO of the Institute for Clinical Evaluative Sciences.

Figure

The provinces hope to shave millions from their pharmaceutical shopping bill by reducing payments for generics.

Image courtesy of © 2011 Thinkstock

The provinces are also peeved that they’re paying higher prices for generics than governments in non-Canadian jurisdictions. “Governments have come to realize they are paying way higher rates than the US [United States],” notes Dr. Jim Wright, professor of medicine at the University of British Columbia in Vancouver.

Before introducing its legislation, Nova Scotia, for example, was paying 63% of a generic’s price compared with its brand-name equivalent.

While that figure will ultimately drop to 35%, it’s still excessive, says Wright. “In my opinion, 35% of the brand name price is still way too high. It should be more like 5%. In the US, where there is more competition, they are this low.”

But there are risks to reducing generic prices, says Sketris. “There is a concern about the financial viability of some pharmacies especially independent pharmacies. Independent pharmacies on average derive a higher percentage of their revenues due to prescription drugs as compared to items in the front store.”

Ensuring future access may be another problem, says Henry. “In the US, they are getting multiple drug shortages. It seems that the very low prices of generics in some cases are making them unattractive to manufacturers.”

Forcing manufacturers to lower costs in one province may also result in them increasing costs in provinces where no cap exists, says Gagnon. “In general, fixing [prices] for generics is not the best policy.”

“We need more bulk purchasing for provinces and a tender process for the lowest [bid],” he adds. “We could achieve more savings and benefit the most from market competition.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 183 (14)
CMAJ
Vol. 183, Issue 14
4 Oct 2011
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Provincial squeeze on generic prices continues
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Provincial squeeze on generic prices continues
donalee Moulton
CMAJ Oct 2011, 183 (14) E1049-E1050; DOI: 10.1503/cmaj.109-3966

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Provincial squeeze on generic prices continues
donalee Moulton
CMAJ Oct 2011, 183 (14) E1049-E1050; DOI: 10.1503/cmaj.109-3966
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The evolving picture of long COVID
  • When are shared decisions false choices?
  • Q&A: As a doctor in a war zone “you have to come to grips with your limitations”
Show more News

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire